Emcure Pharmaceuticals Limited has fixed September 4, 2026, as the record date for determining shareholder entitlement to the final dividend for the financial year ended March 31, 2026. This announcement confirms the timeline for investors expecting a payout of ₹3.60 per equity share, subject to approval at the upcoming Annual General Meeting (AGM). The dividend represents a 36% return on the face value of ₹10 per share.

The Board of Directors recommended this final dividend during its meeting held on May 5, 2026. Payment of the dividend will be made within 30 days from the date of approval by members at the AGM, in compliance with the Companies Act, 2013. The payment is subject to tax deduction at source (TDS) as per the provisions of the Income Tax Act, 1961, and rules framed thereunder, as amended by the Finance Act, 2020.

The 45th AGM of Emcure Pharmaceuticals is scheduled to be held on Monday, September 21, 2026, at 11:00 a.m. (IST). The meeting will be conducted through Video Conferencing (VC) or Other Audio Visual Means (OAVM), in accordance with circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India (SEBI).

Key Dates and Details

The disclosure was made pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholders holding equity shares on the record date will be eligible for the dividend if the recommendation is approved at the AGM.

Emcure Pharmaceuticals Limited has reshuffled its Board of Directors, appointing Raghu Kumar as an Additional Director (Non-Executive and Independent) effective August 06, 2026. The company’s Board approved the appointment on August 06, 2026, following a recommendation from the Nomination and Remuneration Committee. This move coincides with the departure of Chairman Berjis Desai, who will cease to hold office upon the conclusion of the ensuing Annual General Meeting (AGM) on September 21, 2026. Desai expressed unwillingness to seek re-appointment due to his new role as a member of the National Commission for Minorities in New Delhi. Consequently, Satish Mehta, the current Managing Director and CEO, will assume the role of Chairman from September 21, 2026.

The appointments were disclosed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing confirms that Raghu Kumar is not debarred from holding director office by any SEBI order or exchange circulars, including BSE Circular No. LIST/COMP/14/2018-19 and NSE Circular No. NSE/CML/2018/02, both dated June 20, 2018. Kumar is also unrelated to any existing Directors or Key Managerial Personnel of the company. His appointment as an Independent Director for a first term of three consecutive years is subject to shareholder approval at the AGM.

Key Board Changes

Raghu Kumar brings over four decades of experience in the pharmaceutical, healthcare, and consumer products sectors. He has held senior leadership positions at multinational organizations including Allergan, Novartis, and Bayer. Kumar currently serves as the Chairman and Independent Director of Emcutix Biopharmaceuticals Limited, a wholly-owned subsidiary of Emcure. He holds a Bachelor's Degree (Honours) in Economics and Mathematics from St. Stephen's College, University of Delhi, and a Post Graduate Degree in Business Management (Marketing) from the Indian Institute of Management, Ahmedabad.

Satish Mehta, who founded Emcure in 1981, continues to drive the company’s growth strategy. Under his leadership, Emcure has expanded its presence to more than 70 countries through subsidiaries in the UK, Canada, Singapore, Brazil, and other regions. The filing notes that Mehta is the father of Whole-time Directors Samit Mehta and Namita Thapar. The transition of the Chairman role to Mehta ensures continuity in leadership as the company maintains its focus on providing affordable, high-quality healthcare globally.